Education
About Us
Working with TipRanks
Follow Us
Zimmer Biomet Holdings (ZBH)
:ZBH
ZBH Analyst Ratings
Hold
6 Buy
13 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ZBH Stock 12 Month Forecast
Average Price Target
$120.89
▲(8.67% Upside)
| Highest Price Target$140.00 | Average Price Target$120.89 | Lowest Price Target$107.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
Reiterated
03/24/25
Truist Financial
Reiterated
03/13/25
TD Cowen
Reiterated
03/12/25
Morgan Stanley
Reiterated
03/12/25
Wells Fargo
Reiterated
03/07/25
Citi
Reiterated
02/14/25
Barclays
Reiterated
02/10/25
BTIG
Reiterated
02/10/25
Raymond James
Reiterated
02/07/25
Robert W. Baird
Reiterated
02/07/25
Deutsche Bank
$115→$107
Hold
-3.81%
Downside
Reiterated
02/07/25
Zimmer Biomet price target lowered to $107 from $115 at Deutsche BankZimmer Biomet price target lowered to $107 from $115 at Deutsche Bank
Roth MKM
$129
Hold
15.97%
Upside
Reiterated
02/07/25
Roth MKM Sticks to Its Hold Rating for Zimmer Biomet Holdings (ZBH)
JMP Securities
$140
Buy
25.85%
Upside
Reiterated
02/07/25
Analysts Are Bullish on Top Healthcare Stocks: Globus Medical (GMED), Zimmer Biomet Holdings (ZBH)
Canaccord Genuity
$115
Hold
3.38%
Upside
Reiterated
02/06/25
Zimmer Biomet Holdings: Hold Rating Amid Strategic Initiatives and Execution UncertaintiesBottom line: ZBH provided modest beats on the top and bottom line for the Q, with bright spots again including HSD performance in SET and OUS knees. US knees continued to be relatively weaker than competitor Striker (SYK-NYSE: $396.07 | BUY), which saw HSD vs ZBH's MSD growth in the Q, although both fared better than JNJ whose US knee business declined. Additionally, ZBH was able to clear its ERP challenges as it exited 2024 back at pre-ERP shipping levels, incurring a 60-80bps headwind to annual sales from the challenge during the 2H/24. Taking a longer-term view, ZBH continues to stress its LRP commitment to MSD revenue growth, with adj. earnings growing faster than the growth rate of revenues and FCF growing at least 100bps faster than earnings.
RBC Capital
$130→$125
Buy
12.37%
Upside
Reiterated
02/06/25
RBC Capital Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
Reiterated
03/24/25
Truist Financial
Reiterated
03/13/25
TD Cowen
Reiterated
03/12/25
Morgan Stanley
Reiterated
03/12/25
Wells Fargo
Reiterated
03/07/25
Citi
Reiterated
02/14/25
Barclays
Reiterated
02/10/25
BTIG
Reiterated
02/10/25
Raymond James
Reiterated
02/07/25
Robert W. Baird
Reiterated
02/07/25
Deutsche Bank
$115→$107
Hold
-3.81%
Downside
Reiterated
02/07/25
Zimmer Biomet price target lowered to $107 from $115 at Deutsche BankZimmer Biomet price target lowered to $107 from $115 at Deutsche Bank
Roth MKM
$129
Hold
15.97%
Upside
Reiterated
02/07/25
Roth MKM Sticks to Its Hold Rating for Zimmer Biomet Holdings (ZBH)
JMP Securities
$140
Buy
25.85%
Upside
Reiterated
02/07/25
Analysts Are Bullish on Top Healthcare Stocks: Globus Medical (GMED), Zimmer Biomet Holdings (ZBH)
Canaccord Genuity
$115
Hold
3.38%
Upside
Reiterated
02/06/25
Zimmer Biomet Holdings: Hold Rating Amid Strategic Initiatives and Execution UncertaintiesBottom line: ZBH provided modest beats on the top and bottom line for the Q, with bright spots again including HSD performance in SET and OUS knees. US knees continued to be relatively weaker than competitor Striker (SYK-NYSE: $396.07 | BUY), which saw HSD vs ZBH's MSD growth in the Q, although both fared better than JNJ whose US knee business declined. Additionally, ZBH was able to clear its ERP challenges as it exited 2024 back at pre-ERP shipping levels, incurring a 60-80bps headwind to annual sales from the challenge during the 2H/24. Taking a longer-term view, ZBH continues to stress its LRP commitment to MSD revenue growth, with adj. earnings growing faster than the growth rate of revenues and FCF growing at least 100bps faster than earnings.
RBC Capital
$130→$125
Buy
12.37%
Upside
Reiterated
02/06/25
RBC Capital Sticks to Its Buy Rating for Zimmer Biomet Holdings (ZBH)
Best Analysts Covering Zimmer Biomet Holdings
Which Analyst Should I Follow If I Want to Buy ZBH and Sell After:
1 Month
xxx
Success Rate
24/45 ratings generated profit
Average Return
+0.24%
assigned a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +0.24% per trade.
3 Months
xxx
Success Rate
27/45 ratings generated profit
Average Return
+2.37%
assigned a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.37% per trade.
1 Year
Success Rate
31/45 ratings generated profit
Average Return
+5.92%
assigned a buy rating 5 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 68.89% of your transactions generating a profit, with an average return of +5.92% per trade.
2 Years
xxx
Success Rate
27/45 ratings generated profit
Average Return
+6.66%
assigned a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of +6.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ZBH Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
0
0
0
0
Buy
12
13
6
11
9
Hold
23
14
21
26
26
Sell
0
1
2
3
2
Strong Sell
0
0
0
0
0
total
35
28
29
40
37
Each month's total comprises the sum of three months' worth of ratings.
ZBH Financial Forecast
ZBH Stock Forecast FAQ
What is ZBH’s average 12-month price target, according to analysts?
Based on analyst ratings, Zimmer Biomet Holdings’s 12-month average price target is $120.89.
What is ZBH’s upside potential, based on the analysts’ average price target?
Zimmer Biomet Holdings has 8.67% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ZBH a Buy, Sell or Hold?
Zimmer Biomet Holdings has a consensus rating of Hold which is based on 6 buy ratings, 13 hold ratings and 1 sell ratings.
What is Zimmer Biomet Holdings’s price target?
The average price target for Zimmer Biomet Holdings is $120.89. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $107.00. The average price target represents 8.67% Increase from the current price of $111.24.
The highest analyst price target is $140.00 ,the lowest forecast is $107.00. The average price target represents 8.67% Increase from the current price of $111.24.
What do analysts say about Zimmer Biomet Holdings?
Zimmer Biomet Holdings’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.
How can I buy shares of ZBH?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.